Impact of Prior Docetaxel, Extent of Disease, and Prior Bisphosphonates on Hematologic Safety of Ra-223

Impact of Prior Docetaxel, Extent of Disease, and Prior Bisphosphonates on Hematologic Safety of Ra-223

Professor Sartor presents a post hoc analysis of the ALSYMPCA trial evaluating the impact of prior docetaxel or bisphosphonates and extent of disease on the safety of radium-223.

A. Oliver Sartor, MD
Laborde Professor of Cancer Research
Departments of Medicine and Urology
Medical Director of Tulane Cancer Center
Tulane School of Medicine
New Orleans, Louisiana


Click HERE to view the poster presented at the 56th Annual Meeting of the American Society for Radiation Oncology

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe